NOT FOR DISTRIBUTION
Header cover image

Tianjin TEDA Biomedical Engineering

Market Cap

HK$301.2m

Last Updated

2021/05/16 10:59 UTC

Data Sources

Company Financials

Executive Summary

Tianjin TEDA Biomedical Engineering Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of biological compound fertilizer products in the People’s Republic of China. More Details


Snowflake Analysis

Flawless balance sheet and slightly overvalued.

Share Price & News

How has Tianjin TEDA Biomedical Engineering's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 8189 is more volatile than 90% of Hong Kong stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: 8189's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.


Market Performance


7 Day Return

54.4%

8189

0.4%

HK Chemicals

-1.9%

HK Market


1 Year Return

103.8%

8189

46.1%

HK Chemicals

24.3%

HK Market

Return vs Industry: 8189 exceeded the Hong Kong Chemicals industry which returned 46.4% over the past year.

Return vs Market: 8189 exceeded the Hong Kong Market which returned 24.4% over the past year.


Shareholder returns

8189IndustryMarket
7 Day54.4%0.4%-1.9%
30 Day76.7%0.9%-3.4%
90 Day44.5%-1.1%-8.0%
1 Year103.8%103.8%54.5%46.1%29.0%24.3%
3 Year-55.8%-55.8%-23.9%-37.1%0.5%-10.0%
5 Year-91.6%-91.6%24.1%-3.9%58.6%31.9%

Long-Term Price Volatility Vs. Market

How volatile is Tianjin TEDA Biomedical Engineering's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Tianjin TEDA Biomedical Engineering undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 8189 (HK$0.16) is trading below our estimate of fair value (HK$0.4)

Significantly Below Fair Value: 8189 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 8189 is unprofitable, so we can't compare its PE Ratio to the Hong Kong Chemicals industry average.

PE vs Market: 8189 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 8189's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 8189 is overvalued based on its PB Ratio (1.7x) compared to the HK Chemicals industry average (0.8x).


Future Growth

How is Tianjin TEDA Biomedical Engineering forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

17.9%

Forecasted Materials industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Tianjin TEDA Biomedical Engineering has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Tianjin TEDA Biomedical Engineering performed over the past 5 years?

-42.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 8189 is currently unprofitable.

Growing Profit Margin: 8189 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 8189 is unprofitable, and losses have increased over the past 5 years at a rate of 42.8% per year.

Accelerating Growth: Unable to compare 8189's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 8189 is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-0.7%).


Return on Equity

High ROE: 8189 has a negative Return on Equity (-29.59%), as it is currently unprofitable.


Financial Health

How is Tianjin TEDA Biomedical Engineering's financial position?


Financial Position Analysis

Short Term Liabilities: 8189's short term assets (CN¥260.2M) exceed its short term liabilities (CN¥194.3M).

Long Term Liabilities: 8189's short term assets (CN¥260.2M) exceed its long term liabilities (CN¥43.5M).


Debt to Equity History and Analysis

Debt Level: 8189's debt to equity ratio (10.2%) is considered satisfactory.

Reducing Debt: 8189's debt to equity ratio has reduced from 13.1% to 10.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable 8189 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: 8189 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 42.8% per year.


Dividend

What is Tianjin TEDA Biomedical Engineering current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 8189's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 8189's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 8189's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 8189's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 8189's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.4yrs

Average management tenure


CEO

Li Sun (46 yo)

1.42yrs

Tenure

CN¥697,725

Compensation

Ms. Li Sun has been Chairman of the Board and Executive Director of Tianjin TEDA Biomedical Engineering Company Limited since August 20, 2015 and its Chief Executive Officer since December 30, 2019. She ha...


CEO Compensation Analysis

Compensation vs Market: Li's total compensation ($USD108.39K) is below average for companies of similar size in the Hong Kong market ($USD230.31K).

Compensation vs Earnings: Li's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: 8189's management team is considered experienced (2.4 years average tenure).


Board Members

Experienced Board: 8189's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Tianjin TEDA Biomedical Engineering Company Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Tianjin TEDA Biomedical Engineering Company Limited
  • Ticker: 8189
  • Exchange: SEHK
  • Founded: 2000
  • Industry: Fertilizers and Agricultural Chemicals
  • Sector: Materials
  • Market Cap: HK$301.226m
  • Shares outstanding: 1.89b
  • Website: https://www.bioteda.com

Number of Employees


Location

  • Tianjin TEDA Biomedical Engineering Company Limited
  • Tianda Hi-Tech Park
  • Block A2, 9th Floor
  • Tianjin
  • 300457
  • China

Listings


Biography

Tianjin TEDA Biomedical Engineering Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of biological compound fertilizer products in the People’s R...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/16 10:59
End of Day Share Price2021/05/14 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.